Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Moore

Showing results (181-190 of 235) with videos related to

Pageof 24
Sort By:
Biochemistry|March 20, 1990
Use of a site-directed triple mutant to trap intermediates: demonstration that the flavin C(4a)-thiol adduct and reduced flavin are kinetically competent intermediates in mercuric ion reductaseS M Miller, V Massey, D Ballou, et al.
Biochemistry|February 7, 1989
Evidence for the participation of Cys558 and Cys559 at the active site of mercuric reductaseS M Miller, M J Moore, V Massey, et al.
British Journal of Cancer|August 14, 2003
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumoursX Chen, A M Oza, Z Kusenda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2001
Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implicationsJ Dimitroulakos, L Y Ye, M Benzaquen, et al.
Biomaterials|December 31, 2003
Animal models of spinal cord injury for evaluation of tissue engineering treatment strategiesR Talac, J A Friedman, M J Moore, et al.
Molecular Cell|August 21, 2001
Precursor RNAs harboring nonsense codons accumulate near the site of transcriptionO Mühlemann, C S Mock-Casagrande, J Wang, et al.
Neurology|February 1, 1984
HLA antigens in Guillain-Barré syndromeR A Kaslow, J Z Sullivan-Bolyai, B Hafkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancerM J Moore, D Osoba, K Murphy, et al.
Veterinary Pathology|January 30, 2009
Gas bubbles in seals, dolphins, and porpoises entangled and drowned at depth in gillnetsM J Moore, A L Bogomolni, S E Dennison, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2006
Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancerJ T Roberts, H von der Maase, L Sengeløv, et al.
Pageof 24

Showing results (181-190 of 235) with videos related to

Sort By:
Pageof 24
Biochemistry|March 20, 1990
Use of a site-directed triple mutant to trap intermediates: demonstration that the flavin C(4a)-thiol adduct and reduced flavin are kinetically competent intermediates in mercuric ion reductaseS M Miller, V Massey, D Ballou, et al.
Biochemistry|February 7, 1989
Evidence for the participation of Cys558 and Cys559 at the active site of mercuric reductaseS M Miller, M J Moore, V Massey, et al.
British Journal of Cancer|August 14, 2003
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumoursX Chen, A M Oza, Z Kusenda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2001
Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implicationsJ Dimitroulakos, L Y Ye, M Benzaquen, et al.
Biomaterials|December 31, 2003
Animal models of spinal cord injury for evaluation of tissue engineering treatment strategiesR Talac, J A Friedman, M J Moore, et al.
Molecular Cell|August 21, 2001
Precursor RNAs harboring nonsense codons accumulate near the site of transcriptionO Mühlemann, C S Mock-Casagrande, J Wang, et al.
Neurology|February 1, 1984
HLA antigens in Guillain-Barré syndromeR A Kaslow, J Z Sullivan-Bolyai, B Hafkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancerM J Moore, D Osoba, K Murphy, et al.
Veterinary Pathology|January 30, 2009
Gas bubbles in seals, dolphins, and porpoises entangled and drowned at depth in gillnetsM J Moore, A L Bogomolni, S E Dennison, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2006
Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancerJ T Roberts, H von der Maase, L Sengeløv, et al.
Pageof 24